Are Pot Stocks in Danger of Running out of Money?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) could see many acquisitions opportunities arise if other cannabis companies continue bleeding cash.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

There are a lot of changes happening in the cannabis industry, and many companies might not be left standing for long. It’s likely that they’ll end up being acquired — or simply run out of money. One cannabis CEO is very skeptical about what the future will hold for some companies, believing that the money is going to run out sooner or later and that they’ll be left high and dry.

Origin House (CNSX:OH) was acquired earlier this year, and CEO Marc Lustig spoke with BNN Bloomberg recently. In that interview, he expressed doubt as to the health of the industry. He called some of the valuations in the industry “insane” and said, “They can’t be sustained. Ultimately, they’re going to run out of money and the rubber is going to hit the road when they go to ask somebody for more money.”

It’s a fair comment to make given that many companies in the industry are producing significant losses and burning through lots of cash all in the name of expansion and growth. It creates a vicious cycle where more money is needed in order to finance growth — the very growth that bleeds money itself.

Even some of the biggest companies in the industry haven’t been able to avoid those problems. Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has achieved strong sales growth, but without gains or investment losses pulling the company into profitability, I’m not confident that the company would be able to do so on its own through day-to-day operations.

Why relying on growth alone won’t last

Canopy Growth has been playing up the growth game very well, convincing investors to buy based on future expectations rather than on what the reality is today. Nowhere is that more evident than in the company’s so-called deal with Acreage Holdings, which really isn’t a deal until the U.S. legalizes marijuana. It’s a condition that might take years and even then isn’t guaranteed to get done.

However, that was still enough to generate hype around the stock and send it up in price, although it could very easily fall through, especially with not all Acreage shareholders being terribly excited about the possibility of locking into the agreement today.

Convincing investors of growth may be a good strategy for generating excitement around the stock in the short term, but it’s not sustainable beyond a limited time frame. Results will have to follow eventually, and while Canopy Growth may not be a big risk today, the same cannot be said for other pot stocks.

A good example is MedMen Enterprises Inc (CNSX:MMEN), which has struggled so far this year, dropping more than 15% in value since January. Plagued with cash flow problems and now a struggling stock, it’s a company that needs to turn things around in a hurry. Its very growth is putting a lot of strain on its financials. Investors are no longer just buying the stock up based on promises of future growth anymore, which could mean big problems down the road.

Bottom line

The industry is still in its very early stages, and the pretenders won’t last for long. They’ll either be absorbed by bigger players like Canopy Growth or just simply close up shop.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »